• The primary objective is to assess the long term safety and tolerability of sumanirole by measuring Safety labs, ECG monitoring, vital signs and adverse events, over a period of up to 4 years.
  

• Pharmacoeconomics, quality of life, and the long term therapeutic response associated with sumanirole by using Parts II and III of the UPDRS (Unified Parkinson’s Disease Rating Scale).
  
• Part II -- Activities of Daily Living, will be collected in order to record the patient's level of function between visits.
  
• Part III will be used to evaluate motor function.
  
• Three quality of life instruments will be employed: a general scale--the Functional Status Questionnaire, a disease specific scale--the Parkinson's Disease Questionnaire, and a utility scale--the EuroQol.
  

Inclusion Criteria:

• Idiopathic Parkinson's disease
• Modified Hoehn and Yahr Scale Stages 1-4
• Age over 30 years
• Previous participation in prior sumanirole studies

Exclusion Criteria:

• Use of dopamine agonist medications and other medications in defined timeframe
• Unstable dose of CNS active therapies (eg, hypnotics, antidepressants, anxiolytics) within the last 30 days
• Atypical Parkinson's syndromes due to drugs, metabolic disorders, encephalitis, or degenerative diseases
• Dementia
• History of active epilepsy within the past year
• Significant liver disease with defined laboratory criteria
• Significant renal disease with defined laboratory criteria
• Certain cardiac conditions
• Electroconvulsive therapy in the previous 90 days
• Subjects participating in other drug studies or receiving other investigational drugs within previous 30 days
• Positive pregnancy test at Screen
• Unwillingness to use adequate contraceptive methods
• Lactating women
• History of stereotaxic brain surgery
• Malignant melanoma or history of treated melanoma